Zarontin (ethosuximide) NDC 0071-2418

NDC codes

FDA NDC Directory

Product NDC (as listed)0071-2418Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00071-2418Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0071-2418-19	00071241819	1 BOTTLE, PLASTIC in 1 CARTON (0071-2418-19) / 474 mL in 1 BOTTLE, PLASTICMarketed from Jun 1, 2022

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zarontin
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: Parke-Davis Div of Pfizer Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 080258
Marketing start: Mar 10, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0071-2418_6afa95d3-162a-4fbb-ab47-561f4ee7771aSPL ID 6afa95d3-162a-4fbb-ab47-561f4ee7771aSPL set ID 7bf3e616-45e8-4469-a75d-4d824ce951eaRxCUI 251322, 755357UNII 5SEH9X1D1D
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400071241819 followed by a unit qualifier and the quantity

Package 00071-2418-19. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 13, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 080258

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 080258
Product	Strength	Form · route	Labeler	Product NDC
Ethosuximide	Ethosuximide 250 mg/5mL	SolutionOral	Mylan Pharmaceuticals Inc.	59762-2350